How many investments has Ysios Capital made?

Ysios Capital has 54 tracked investments, 8 of which have exited, including 1 dated in the last 24 months.

What stage does Ysios Capital invest at?

Ysios Capital invests at the Seed, Series A, Series B, Series C, Growth, Late Stage stages.

What is Ysios Capital's typical check size?

Ysios Capital typically writes checks of $5.4M – $21.6M.

Where is Ysios Capital located?

Ysios Capital is headquartered in Barcelona, ES.

Does Ysios Capital lead rounds?

Ysios Capital typically participates in rounds rather than leading them.

Who does Ysios Capital co-invest with?

Ysios Capital most often shares deals with Kurma Partners, Andera Partners, Criteria Bio Ventures, among 71 tracked co-investors.

Ysios Capital

Venture capital

Barcelona · Seed–Late Stage · 25 people tracked

Also known as Ysios

★ Follow + Add to CRM ⤳ Find an introduction

Find your way into Ysios Capital

2,068 people in our graph share verified history with the Ysios Capital team — schools, employers, funds. One of them is your warm intro.

João Vieiraunlockedknows Pamela Klein · together at argenx (overlapped)

knows the team · via Ona Therapeutics

×3knows the team · via Ysios Capital

×5knows the team · via Five Elms Capital

×2knows the team · via Vida Ventures

✨ Fox Verdict

Investment thesis

Ysios Capital backs highly innovative life sciences and biotech ventures worldwide, providing capital and resources to develop novel therapies targeting indications with high unmet medical needs. The firm invests across Europe and the United States, favoring companies with strong scientific foundations and the potential to make a meaningful impact on patients and society. Ysios combines scientific, financial, and entrepreneurial expertise to support the growth of promising biotech companies, and integrates ESG and impact measurement through its proprietary Y-mpact methodology, focusing on promoting health and well-being, enhancing workforce diversity in biotech, and tracking ESG performance across its portfolio.

Invests inBiotech Digital Health Healthtech Impact & Social Good Medical Devices Barcelona Denmark Europe France Global Netherlands North America Spain Sweden Switzerland United States

Source: firm website, verified Sep 27, 2026.

Stage

Seed–Late Stage

Check

$5.4M – $21.6M

Barcelona, ES

Leads rounds

Follows

Instruments

Equity

Founded

2008

AUM

$400M

Tracked investments

IPOs

Acquisitions

Team · 25 people

from the firm's website & curated

Joan Perelló· Managing Partner· Greater Palma de Mallorca Metropolitan Areain

Joan Perelló is Managing Partner at Ysios Capital and has 20 years of management experience in roles including CEO, non-executive director, and chairman. He co-founded Sanifit, where he served as CEO and oversaw the development of its lead candidate SNF472 through clinical evaluation, and he also founded Conceptio Biotech and chairs the boards of CIRCE Crystal Engineering and Mexbrain. He holds a PhD from the University of the Balearic Islands, where he teaches Analytical and Clinical Chemistry as an Associate Professor, and is co-author of over 60 peer-reviewed publications and co-inventor of 17 international patents.

Pamela Klein· Founder and Principal, PMK BioResearch· San Francisco, California, United Statesin

Dr. Pamela M. Klein is founder and principal of PMK BioResearch, providing advisory and strategic consulting to the biotechnology industry, and serves as consulting Chief Medical Officer of Olema Oncology. She previously held Chief Medical Officer roles at several biotech companies, including Intellikine (acquired by Takeda), and worked at Genentech from 2001 to 2008, ending as Vice President of Development where she oversaw development of drugs such as trastuzumab, rituximab, pertuzumab and erlotinib. She earlier co-founded and served as research director for the National Cancer Institute–Navy Breast Care Center, holds a biology degree from California State University Northridge and a medical degree from Loyola University Chicago's Stritch School of Medicine, and trained in internal medicine and medical oncology.

Arturo Urrios· Leads early-stage investments and company creation· Barcelona, Catalonia, Spainin

Arturo Urrios leads early-stage investments and company creation at Ysios Capital. He previously worked at M Ventures and Wellington Parties, where he was involved in financings including Riffyn, Plexium, eGenesis, Themis Biosciences and Seamless Therapeutics. He helped create Seamless Therapeutics in 2022, leading its business development and corporate strategy and securing a collaboration with Lilly. He holds a BSc in Human Biology, an MSc in Biomedical Research, an MBA, and a PhD in Biomedicine, and co-founded the YVC Collective.

a•••@ysioscapital.comreveal

Cristina Garmendia· General Partner· Madrid, Community of Madrid, Spainin

Cristina Garmendia supports institutional relations, investor relations, and fundraising at Ysios Capital. She previously served as Spain's Minister for Science and Innovation (2008–2011), where she oversaw reforms including the Spanish Innovation Strategy and the Law for Science, Technology and Innovation. She holds a Bachelor's in Genetics from the University of Seville, a PhD in Molecular Biology from the Universidad Autónoma de Madrid, and an MBA from IESE at the University of Navarra.

c•••@ysioscapital.comreveal

Guillem Laporta· Investment professional· Spainin

Guillem Laporta makes and manages investments at Ysios Capital and handles investor reporting. He has 15 years of venture capital experience and previously worked at the Edmond de Rothschild Group (now Andera Partners) in Paris, where he was involved in investments across Europe and the United States, including Reviral, Axonics Modulation, Sanifit and Verona Pharma. He is a CFA charterholder and holds bachelor's degrees in Biotechnology from the Universitat Autonoma de Barcelona and in Business Administration from the Universitat Pompeu Fabra.

g•••@ysioscapital.comreveal

Joël Jean-Mairet· Managing Partner· Barcelona, Catalonia, Spainin

Joël Jean-Mairet is Managing Partner at Ysios Capital, where he oversees management, strategy and day-to-day operations. In 2001 he co-founded Glycart Biotechnology and served as its CEO until its sale to F. Hoffmann-La Roche four years later; Glycart originated the anti-CD20 antibody obinutuzumab/Gazyva. He holds an MSc in Biotechnology and a PhD in Cell Biology and Immunotherapeutics, both from ETH Zürich.

j•••@ysioscapital.comreveal

Jordi Xiol· Partner· Barcelona, Catalonia, Spainin

j•••@ysioscapital.comreveal

Julia Salaverría· Managing Partner· San Sebastián, Basque Country, Spainin

Julia Salaverría is Managing Partner at Ysios Capital, where she oversees investor relations and corporate development. She previously spent 2000–2007 as a Director at Spanish venture capital group Talde, handling fundraising, investor relations and biotech investments, and earlier served as Principal Economist in the Research Department of the Bank of Spain. She holds a Bachelor's degree in Economics from the Universidad Autónoma of Madrid, an MBA from the University of Deusto, and a PADE degree from IESE at the University of Navarra.

j•••@ysioscapital.comreveal

Karen Wagner· General Partner· Zurichin

Karen Wagner is a Managing Partner at Ysios Capital, where she works on therapeutic investments and helps identify and evaluate opportunities. She joined Ysios in 2008 after more than a decade in biotech and pharma business development, having begun her career as a management consultant in McKinsey & Company's healthcare practice and later served as Director of Business Development at Ingenium Pharmaceuticals. She previously worked at Glycart Biotechnology and, following its acquisition by F. Hoffmann-La Roche, led business development and alliance management at Roche; she holds a Master's in Molecular Biology and a PhD in Cell Biology from the University of Konstanz.

k•••@ysioscapital.comreveal

Thomas Harth· Partner· Barcelona, Catalonia, Spainin

t•••@ysioscapital.comreveal

Nico Takano Meier· Managing Partner· Austin, Texas, United States

Antoni Ribas· Venture Partner

Antoni Ribas, M.D., Ph.D., is a physician-scientist and Professor of Medicine, Surgery, and Molecular and Medical Pharmacology at UCLA, where he directs the Tumor Immunology Program at the Jonsson Comprehensive Cancer Center and the Parker Institute for Cancer Immunotherapy Center. His research focuses on malignant melanoma, gene-engineered T cells, PD-1 blockade, and BRAF-targeted therapies, and he contributed to the clinical development of several FDA-approved drugs including pembrolizumab, vemurafenib, and dabrafenib. He currently serves as President of the American Association for Cancer Research and is an elected member of the U.S. National Academy of Medicine.

Carlos Garcia-Echeverria· Scientific and Strategic Advisor· Spainin

Dr. Garcia-Echeverria has held senior scientific and executive roles at biopharmaceutical companies including EQRx, Sanofi, and Novartis, with a focus on drug discovery and early-stage clinical development. He currently works as a scientific and strategic advisor to biopharma companies and venture capital firms, advising on drug discovery programs, development strategies, and partnerships. He holds a PhD in organic chemistry from the University of Barcelona and has authored 190 peer-reviewed publications and secured 45 granted patents.

Carlos Paya· Venture Partner· Seattle, Washington, United Statesin

Dr. Carlos Paya has held leadership roles across academic medicine, large pharmaceutical companies, and biotech startups, focusing on strategic execution, pipeline growth, product lifecycle management, and fundraising. He previously served as president and CEO of Immune Design Corp. until its 2019 acquisition by Merck, and held senior roles at Elan Pharmaceuticals and Eli Lilly. Earlier in his career he spent nearly a decade at the Mayo Clinic-Rochester as a professor of medicine, immunology, and pathology and vice dean of its clinical investigation program.

s•••@ysioscapital.comreveal

David L. Lacey· Venture Partner· Cambria, California, United Statesin

Dr. David Lacey spent 17 years at Amgen, where he led the company's Discovery Research organization and its team of over 1,200 scientists working on drug discovery across haematology, oncology, inflammation, metabolic disorders, and neuroscience. He contributed to bone biology research underlying the development of Prolia (denosumab) and XGEVA, and previously served on the faculty at Washington University Medical Center in St. Louis. He holds a Bachelor's degree in Biology and an MD from the University of Colorado and is board certified in anatomical pathology.

Lance Berman· Venture Partner· Barcelona, Catalonia, Spainin

Lance Berman has over 20 years of operational experience across large pharmaceutical companies and biotech start-ups. Before joining Ysios Capital, he served as Chief Medical Officer and Senior Vice President at Relypsa, where he built and led clinical development, medical affairs, and drug safety functions and contributed to the company's fundraising and IPO; the company secured FDA and EMA approval for Veltassa under his clinical leadership. He previously held roles including Chief Medical Officer at Aelix Therapeutics, CMO and Head of Business Development at CPEX Pharmaceuticals, leadership positions at Pfizer, and Director of Clinical Research at Schering-Plough. He holds Bachelor's degrees in Medicine and Surgery from the University of Cape Town and an MSc in Pharmaceutical Medicine from Hibernia College–Harvard University–Royal College of Surgeons (Dublin).

l•••@outlook.comreveal

Almudena Méndez· Associate, Advisory team (Telescope Biotech Fund)· Barcelona, Catalonia, Spainin

Almudena Méndez is an Associate on the Advisory team at the Telescope Biotech Fund, where she works on sourcing and analyzing investment opportunities across scientific and business dimensions. She previously spent more than five years at the Centro Nacional de Biotecnología (CNB-CSIC) as an FPU fellow, researching T cell-based cancer immunotherapies, and completed an internship in cancer immunotherapy at the Institute for Research in Biomedicine in Bellinzona, Switzerland. She holds a Bachelor's in Biotechnology, an MSc in Computational Biology, and a Master in International Leadership from the Universidad Politécnica de Madrid, plus a PhD in Molecular Biosciences from the Universidad Autónoma de Madrid.

a•••@ysioscapital.comreveal

Catalina Cuchy· Executive Assistant· San Sebastiánin

Catalina Cuchy provides administrative and operational support to the Managing Partners and investors at Ysios Capital, handling office operations and logistics from the San Sebastián office. She previously worked as Assistant Manager at Bois et Fer and as Administrative Assistant at the Gipuzkoa Mercantile Federation. She earned a Bachelor's degree in Management Assistance from the University of Navarra's ISSA School of Management Assistants.

c•••@ysioscapital.comreveal

Iñigo López-Huerta· Responsible for Financial and Compliance matters· Greater Bilbao Metropolitan Areain

Íñigo oversees financial and compliance matters at Ysios, bringing over a decade of experience in the financial sector. He previously served as an audit manager at PricewaterhouseCoopers (PwC), working with banking and capital markets clients including collective investment funds and venture capital firms in Spain. He holds a Business Administration degree and MBA from Universidad de Deusto (La Comercial), a Master's in Auditing from Universidad de Alcalá, and completed a management development program at ESADE.

i•••@ysioscapital.comreveal

Laura Argelich· Associate· Barcelona, Catalonia, Spainin

Laura Argelich helps identify and evaluate investment opportunities at Ysios Capital from scientific and business angles. Before joining the firm, she worked in the Stem Cells and Neurogenesis unit at Ospedale San Raffaele in Milan, where her research focused on direct reprogramming approaches and dopaminergic neurons in Parkinson's disease. She holds a master's degree in Biochemistry, Molecular Biology and Biomedicine from the Universitat Autònoma de Barcelona and a PhD in Molecular Medicine from the Università Vita-Salute San Raffaele.

l•••@ysioscapital.comreveal

Malgorzata Rogalska· Associate· Barcelona, Catalonia, Spainin

Malgorzata Rogalska evaluates investment opportunities at Ysios Capital from scientific and business angles, with more than 15 years in life sciences and expertise in RNA therapeutics and gene regulation across genetic diseases, oncology, and metabolic disorders. She previously worked as a senior researcher at the Centre for Genomic Regulation in Barcelona and has published research including first-author papers in Nature and Science. She holds a Bachelor's and MSc in Biotechnology from the Technical University of Lodz and a PhD in Molecular Biology from ICGEB in collaboration with the University of Cambridge.

m•••@ysioscapital.comreveal

María Vega de Seoane· Controller· San Sebastián, Basque Country, Spainin

Míriam Cortés· Executive Assistant & Comms.· Greater Barcelona Metropolitan Areain

Míriam Cortés supports Ysios Capital's Managing Partners and investors, and handles media relations along with office operations including IT and administrative support. She has over 10 years of experience as an executive assistant supporting C-suite executives, coordinating international logistics and events, and assisting with investor relations, and previously worked as assistant to the Legal and Fleet Director at Vueling Airlines. She holds a Bachelor's degree in Media and Communication and a graduate degree in Business Communication from Universitat Pompeu Fabra, plus a graduate degree in Social Media & Community Management from the University of Barcelona.

m•••@ysioscapital.comreveal

Sriram Balusu· Associate, Advisory Team (Telescope Biotech Fund)· Leuven, Flemish Region, Belgiumin

Sriram Balusu is an Associate on the Advisory team at the Telescope Biotech Fund, where he sources and analyzes investment opportunities combining scientific and business perspectives. He previously spent over a decade in research at VIB in Belgium, with doctoral work on the blood–central nervous system barrier and postdoctoral research on Alzheimer's disease, including developing mouse models and therapeutic strategies. He has authored more than 20 publications, including papers in Science, Neuron, and Acta Neuropathologica, and holds a PhD in Biotechnology and Biochemistry from Ghent University.

s•••@ysioscapital.comreveal

Wen Wen Cheng· General Counsel and Head of ESG· Barcelona, Catalonia, Spain

What they invest in

from 45 of 54 portfolio companies

Biotech ×37Healthtech ×32Medical Devices ×23Digital Health ×12Deep Tech ×8FemTech ×3AI & Machine Learning ×2Consumer ×2

HQs:United States×13Spain×5Switzerland×3Denmark×3France×3Netherlands×3

Who they back

founder profiles across 12 portfolio companies

50%

solo founders

6 of 12 mapped founding teams

~6 yrs

old at investment

median across 9 dated deals

Founding team size:solo founder×62 founders×43 founders×2

Investments · 54 tracked

founders shown can be your intro path

By year:2025 · 1 2024 · 1 2023 · 2 2022 · 2 2021 · 3 2020 · 5 2018 · 2 2017 · 4 2015 · 1 2014 · 1 2011 · 224 dated

Aura Biosciencesaurabiosciences.com in 𝕏NASDAQ: AURASeries B · Mar 2015 · $21M

Aura Biosciences develops Virus-Like Drug Conjugates (VDCs), a platform using Virus-Like Particles conjugated with drugs or loaded with nucleic acids to target solid tumors.

BiotechHealthtechMedical DevicesCambridge, US

Elisabet de los Pinos, Ph.D.(Executive Officer, Director)Elisabet de los Pinos(Founder)inMichael Wyzga(Executive Officer)Dale Pfost, Ph.D.(Director)Alan E. Walts, Ph.D.(Director)Lewis Geffen(Executive Officer)

Co-investorsAdvent Life Sciences Chiesi Ventures Columbus Venture Partners Droia Ventures Foresite Capital Jazzya Investments +4 more

CVRxcvrx.com in 𝕏NASDAQ: CVRXJul 2020 · $12M

CVRx develops Barostim, an implantable medical device that uses baroreceptor activation to treat heart failure patients and improve their functional capacity and quality of life.

BiotechHealthtechMedical DevicesAustin, US

Craig Palmer(Executive Officer)inNadim Yared(Executive Officer, Director)inDean Bruhn-Ding(Executive Officer)inJohn Brintnall(Executive Officer)inLiz Galle(Executive Officer)Kevin Hykes(President, Chief Executive Officer & Director)in

Co-investorsABS Ventures New Enterprise Associates (NEA)Treo Ventures, Llc Windham Capital Partners Action Potential Venture Capital Ltd.Hatteras Venture Partners +1 more

KALA BIOkalarx.com inNASDAQ: KALASeries B · Apr 2014 · $23M

A biopharmaceutical company developing an artificial intelligence infrastructure platform designed for on-premises deployment in biotechnology and pharmaceutical research environments, serving biotech firms and pharma companies seeking secure access to advanced AI capabilities while retaining control over proprietary biological data; the company is also evaluating strategic alternatives for its legacy mesenchymal stem cell secretome assets after discontinuing its lead rare eye disease therapeutic program.

BiotechArlington, US

Justin Hanes(Director)inKevin Pojasek(Executive Officer)inDarius Kharabi(Executive Officer)in Todd Bazemore(Executive Officer)in Mark Iwicki(Executive Officer, Director)inMary Reumuth(Executive Officer)in

Co-investorsLongitude Capital SR One Capital Management Atlas Venture Lux Capital RA Capital Third Rock Ventures

Mineralys Therapeuticsmineralystx.com in 𝕏NASDAQ: MLYSSeries B · Jun 2022 · $120M

Mineralys Therapeutics is a clinical-stage pharmaceutical company developing lorundrostat, a treatment targeting dysregulated aldosterone.

BiotechHealthtechRadnor, US

Eric Warren(Chief Commercial Officer)in Alex Gold(Chief Medical Officer)inAdam Levy(Executive Officer)Alexander Asam(Director)

BoardBrian Taylor Slingsby(Founder & former CEO / Board Director)Olivier Litzka(Director)in

Co-investorsAndera Partners HBM Healthcare Investments HBM Partners Samsara BioCapital SR One Capital Management Adams Street Partners +3 more

Engrail Therapeuticsengrail.com in✓ verified

Engrail Therapeutics is a clinical-stage pharmaceutical company developing precision-targeted therapeutics for neupropsychiatric and neurodevelopmental disorders.

BiotechDigital HealthMedical DevicesSan Diego, US

Stephen(Co-founder, EVP Research & Development and Chief Development Officer)Paul Cayer(Chief Financial Officer)inVikram(President and Chief Executive Officer)Kimberly(Chief Scientific Officer)Quentin(Chief Technical Officer)

Co-investorsForesite Capital Longwood Fund Norwest Venture Partners Pivotal Life Sciences RiverVest Venture Partners abrdn plc +4 more

Kynexiskynexistx.com in 𝕏✓ verified

Kynexis is a clinical-stage biotech developing KYN-5356, an oral small-molecule KAT-II inhibitor targeting the kynurenine pathway to improve cognition in neurological diseases.

BiotechDeep TechHealthtech

Robert Schwarcz(Scientific Co-founder)Carol Tamminga(Scientific Co-founder & Chair of the SAB)Christer Köhler(Founding Director)inKees Been(Chief Executive Officer)inJens Wendland(Chief Medical Officer)inNeil Swami(Chief Business Officer)

Co-investorsForbion Novartis Venture Fund Sunstone Capital

Memo Therapeutics AGmemo-therapeutics.com inMay 2024✓ verifiedacquired by Clementia

Memo Therapeutics develops therapeutic antibodies targeting viral infections to improve treatment outcomes for patients with conditions like BKPyV infection in kidney transplant recipients and oncological viral diseases.

BiotechMedical DevicesZurich, CH

Co-investorsKurma Partners Pureos Bioventures Adjuvant Capital Fresenius Medical Care Ventures Verve Ventures redalpine

Northsea Therapeuticsnorthseatherapeutics.com in✓ verified

NorthSea Therapeutics is a clinical-stage biopharmaceutical company developing oral fatty acid-derived therapies for liver and metabolic diseases, including intestinal failure-associated liver disease (IFALD), severe hypertriglyceridemia, and MASH.

BiotechDigital HealthHealthtech

Co-investorsNew Science Ventures venBio Partners BGV Novo Holdings BioGeneration Ventures Forbion +1 more

Splice Biosplice.bio in 𝕏Sep 2020✓ verified

SpliceBio develops genetic medicines using a proprietary protein splicing platform to treat diseases caused by mutations in large genes.

BiotechDeep TechDigital HealthBarcelona, ES

Dr. Vila-Perelló(CEO)Dr. Frutos(Co-founder)

Co-investorsAsabys Partners Novartis Venture Fund Roche Venture Fund Sanofi Ventures Criteria Bio Ventures New Enterprise Associates (NEA)+3 more

Synendossynendos.com in✓ verified

Synendos is a biotech company developing selective endocannabinoid reuptake inhibitors targeting the endocannabinoid system to treat neuropsychiatric disorders.

BiotechDeep TechDigital HealthMental HealthBasel, CH

Prof. Jürg Gertsch(Founder)Dr. Andrea Chicca(Co-Founder & Chief Executive Officer)Dr. Simon Russell(Co-Founder & Chief Commercial Officer)

Co-investorsKurma Partners Sunstone Capital

VarmXvarmx.com inMay 2023✓ verified

VarmX develops VMX-C001, a therapeutic medicine for treating severe bleeding in patients on Factor Xa anticoagulants and for emergency surgery settings.

BiotechHealthtechMedical Devices

Pieter Reitsmain John Glasspool(Chief Executive Officer)in

Co-investorsBioGeneration Ventures Inkef Sound Bioventures EIC EQT Life Sciences UNIIQ +2 more

Vivet Therapeuticsvivet-therapeutics.com in 𝕏✓ verified

Vivet Therapeutics is a clinical-stage biotechnology company developing recombinant adeno-associated virus (rAAV) gene therapies for rare, inherited metabolic diseases, including Wilson's Disease and cerebrotendinous xanthomatosis.

BiotechHealthtechParis, FR

Co-investorsHealthCap Kurma Partners Novartis Venture Fund Roche Venture Fund Columbus Venture Partners Eurazeo +1 more

Acqusticacqustic.com in 𝕏Pre-Seed · Oct 2017 · $95K

Acqustic is a music community platform connecting independent musicians, industry companies, brands, and fans, offering new releases, concerts, videos, and playlists.

ConsumerMedia & EntertainmentSocial

Esteve Lombarte Llado(Founder)in

Co-investorsCOREangels Draper B1

Adcendoadcendo.dkSeries A · Apr 2021 · $62M

Adcendo develops antibody-drug conjugates (ADCs) engineered to treat cancers with high unmet medical needs.

BiotechDigital HealthMedical Devices

Co-investorsVida Ventures HealthCap Jeito Capital

AELIX Therapeuticsaelixtherapeutics.com in 𝕏

AELIX Therapeutics is a company developing a therapeutic HIV vaccine intended for use in HIV cure and eradication strategies.

BiotechHealthtechBarcelona, ES

Co-investorsCriteria Bio Ventures

AM Pharmaam-pharma.com inSep 2011 · $40M

AM-Pharma develops ilofotase alfa, a recombinant alkaline phosphatase enzyme therapy, and is studying it as a treatment for adults with hypophosphatasia (HPP), a rare inherited metabolic bone disease.

BiotechHealthtech

Co-investorsAndera Partners Kurma Partners Forbion

Anaconda Biomedanaconda.bio in 𝕏

Anaconda Biomed develops next-generation endovascular access and protection devices.

BiotechHardwareHealthtechMedical DevicesBarcelona, ES

Trent Reutiman(CEO)inHendrik Lambert(Vice-President of Clinical & Regulatory Affairs)inDr. Iñaki Galve Jordi Cardona in

BoardMaria Jose Alonso

Co-investorsAsabys Partners European Investment Bank Innogest Capital

Babyscriptsbabyscripts.com in 𝕏Jun 2017 · $5.7M

Babyscripts provides a maternity care platform with remote patient monitoring, risk screening, and care management services for pregnant and postpartum patients.

Digital HealthFemTechHealthtech

Juan Pablo Segura(Founder)in Anish Sebastian(Founder & CEO)in

Co-investorsCU Healthcare Innovation Fund MemorialCare Innovation Fund Philips Ventures Builders + Backers Civilization Ventures Management, Llc IrishAngels +4 more

Babyscriptsgetbabyscripts.com in 𝕏Jun 2017 · $5.7M

Babyscripts offers remote patient monitoring and care management tools for maternal health, serving health systems, private practices, and payers to identify clinical and social risks during pregnancy and postpartum periods.

Digital HealthFemTechHealthtechSaaS

Co-investorsAAF Management Ltd.CU Healthcare Innovation Fund IrishAngels P5 Health Ventures Philips Ventures

BioClin Therapeutics inMay 2018

BiotechSan Leandro, US

Steve Abella(Chief Medical Officer)inGraeme Currie(Chief Operating Officer)in Stephen W. Lau(President, Chief Executive Officer, and Treasurer)in Kenneth Schwartz(Executive Officer)in Eric Yuen(Executive Officer)in Marten Steen(Director)in

Co-investorsHealthCap Inkef Sectoral Asset Management Sofinnova Ventures

BioVexin 𝕏acquired by Amgen · Jan 2011 · $425M

Amgen is a biopharmaceutical company that develops and manufactures therapeutics targeting oncology, cardiovascular disease, inflammation, bone health, neuroscience, and other serious illnesses.

BiotechDigital HealthHealthtechMedical DevicesThousand Oaks, US

George B. Rathmann(First CEO)

BoardWilliam K. Bowes

Co-investorsAsset Management Company BOM CWRU Technology Ventures Mayfield Fund US Venture Partners

Clementiaipsen.com in 𝕏

Ipsen is a biopharmaceutical group that publishes financial, legal, and non-financial reporting for shareholders, investors, and the public through documents such as its Universal Registration Document.

BiotechHealthtech

Co-investorsNew Enterprise Associates (NEA)

Corwavecorwave.com in 𝕏

CorWave produces a ventricular assist pump for advanced heart failure patients, delivering pulsatile flow to provide mechanical cardiac support for transplant candidates, non-transplant-eligible patients, and recovery cases.

BiotechDeep TechHealthtechMedical Devices

Louis de Lillers(CEO)in Andreas Fleischli(CTO)in

Co-investorsSeventure Partners Sofinnova Partners

Cytoki Pharmacytokipharma.com inSeries A · May 2021 · $45M

Cytoki is a biotech company developing IL-22-based therapeutics using lipidation technology to treat metabolic diseases such as obesity and type 2 diabetes, as well as conditions involving epithelial injury like inflammatory bowel disease.

BiotechHealthtechVærløse, DK

Rasmus Jorgensen(CEO & Founder)in

Co-investors+ND Capital Seventure Partners

EndoSensecardiovascular.abbott in 𝕏

Abbott's cardiovascular division provides cardiac and vascular medical devices and technologies, including electrophysiology products for treating conditions such as AFib and remote hemodynamic monitoring for heart failure.

HealthtechMedical Devices

Co-investorsAndera Partners

Fusion Pharmaceuticalsfusionpharma.com in 𝕏

Fusion Pharma develops targeted alpha therapeutics that link alpha-emitting medical isotopes to molecules targeting biomarkers on cancer cell surfaces to selectively kill tumor cells.

BiotechHealthtech

John Valliant(Founder)in

Co-investorsFACIT (Fight Against Cancer Innovation Trust)HealthCap Lumira Ventures Pivotal Life Sciences Seroba Life Sciences Venture Ontario +6 more

Galecto Biotechgalecto.com

Damora Therapeutics is a biotechnology company developing subcutaneous biologics as targeted, disease-modifying treatments for patients with mutant calreticulin (mutCALR)-driven myeloproliferative neoplasms such as essential thrombocythemia and myelofibrosis.

BiotechMedical Devices

Jennifer Jarrett(Chief Executive Officer & Board Director)in Sherwin Sattarzadeh(Chief Operating Officer)inBecker Hewes(Chief Medical Officer)Garrett Winslow(General Counsel)in Jim Baker(Chief Corporate Affairs Officer)inBrian Burkavage(Senior Vice President, Finance)in

Co-investorsEIR Ventures Hadean Ventures M Ventures SEED Capital Denmark Seventure Partners Sunstone Capital +2 more

Inbiomotioninbiomotion.comSeries A · Jan 2021 · $2M

InBioMotion offers a biomarker test that analyzes MAF gene levels to assess prognosis and guide personalized bisphosphonate treatment in early breast cancer patients.

BiotechDigital HealthMedical Devices

BoardProf Rob E. Coleman(Chairman)

Co-investorsAsabys Partners Criteria Bio Ventures Alta Life Sciences

Kidneykidney.org in

The National Kidney Foundation works to eliminate preventable kidney disease, accelerate innovation in patient care, and address structural inequities in kidney treatment and transplantation services.

HealthtechImpact & Social Good

Co-investorsBioGeneration Ventures Epidarex Capital Roche Venture Fund Scottish National Investment Bank Sofinnova Partners

LAVA Therapeuticslavatherapeutics.com in 𝕏Series C · Sep 2020 · $83M

LAVA develops the Gammabody platform, which generates bispecific antibodies that activate gamma-delta T cells to treat cancer by directing immune cells to tumors and triggering anti-cancer immune responses.

AI & Machine LearningBiotechHealthtechMedical Devices

Ton AdanginHans van der Vliet(Head of Innovation)inSteve Hurly(Chief Executive Officer)Oxana Polyakova(Chief Scientific Officer)in

Co-investorsMRL Ventures Fund Sanofi Ventures Gilde Healthcare Novo Holdings REDMILE

MedLumicsmedlumics.comSeries A · Dec 2011 · $5M

Co-investorsAndera Partners Kurma Partners Seroba Life Sciences VI Partners

Minoryx Therapeuticsminoryx.com inSeries A · May 2022 · $22M

Minoryx is a registration-stage biotech company developing novel therapies for severe, orphan genetic diseases of the central nervous system, with a lead compound (leriglitazone) in clinical trials for conditions including cerebral adrenoleukodystrophy, Friedreich's Ataxia, and Rett syndrome.

BiotechDeep TechHealthtechMedical DevicesMataró, ES

Marc Martinell(Co-Founder & Chief Executive Officer)in

Co-investorsChiesi Ventures Criteria Bio Ventures Fund+Invivo Capital Partners Kurma Partners Roche Venture Fund +5 more

NCT05101187clinicaltrials.gov

ClinicalTrials.gov is a public registry and results database of clinical studies conducted around the world, maintained by the U.S.

Digital HealthHealthtech

Co-investorsAdvent Life Sciences Colorado BioScience Association

Neurona Therapeuticsneuronatherapeutics.com inApr 2025 · $102M

Neurona Therapeutics is a clinical-stage biotherapeutics company developing allogeneic neural cell therapies to treat chronic disorders of the nervous system.

BiotechDeep TechHealthtechSouth San Francisco, US

Cory Nicholas(Executive Officer, Director, Promoter)inJames Stutz(Chief Financial Officer and Chief Business Officer)in Catherine Priest(Chief Development Officer)in Gautam Banik(Chief Technology Officer)inEduardo Dunayevich(Chief Medical Officer)inArnold Kriegstein(Director)

Co-investorsBerkeley Frontier Iaso Ventures The Column Group Alexandria Fidelity Investments LYFE Capital +7 more

Onaona.com in 𝕏Jun 2020

Ona provides cloud-based agent infrastructure that runs developer tasks in isolated environments while laptops are closed, automating workflow execution through events, schedules, and pull requests.

AI & Machine LearningCloud ComputingDeveloper Tools

Co-investorsBright Pixel Capital Crane Venture Partners Pebblebed Preston-Werner Ventures Alta Life Sciences Asabys Partners +4 more

ONAweareona.co

WE ARE ONA is a creative culinary studio that designs bespoke dining experiences for luxury and artistic brands, combining strategy, design, and production to reinforce emotional connections between brands and their audiences.

ConsumerFoodTechMarketplacesParis, FR

Luca Pronzato(Founder)

Co-investorsWind Venture Columbus Venture Partners Korys Mérieux Equity Partners

Ona Therapeuticsona-therapeutics.com in 𝕏Series A · Jun 2020 · $34M

Ona Therapeutics develops therapeutic antibodies targeting lipid metabolism to treat advanced and metastatic cancers, including liposarcoma.

BiotechHealthtechMedical Devices

Co-investorsAsabys Partners Fund+Korys Mérieux Equity Partners Alta Life Sciences Bpifrance +2 more

Oxtheraoxthera.com

OxThera develops a live biotherapeutic product based on oxalate-degrading bacteria to treat primary hyperoxaluria and other rare kidney diseases.

BiotechHealthtechMedical DevicesStockholm, SE

Elisabeth Lindner(Chief Operating Officer)Mats-Olof Wallin(Chief Financial Officer)Milt Allison

Co-investorsHealthCap Sunstone Capital

Prexton Therapeuticsprextontherapeutics.com inacquired by Lundbeck

Prexton Therapeutics was a biopharmaceutical company developing novel therapies for Parkinson's disease, including its lead mGluR4 modulator candidate foliglurax.

BiotechHealthtechMedical DevicesCopenhagen, DK

Co-investorsCardinal Partners M Ventures Seroba Life Sciences Sunstone Capital Forbion

ReproNovorepronovo.com in

ReproNovo develops therapeutic solutions for male and female fertility and women's health conditions like adenomyosis, targeting unmet medical needs in reproductive medicine.

BiotechFemTechHealthtechMedical DevicesLausanne, CH

Co-investorsJeito Capital M Ventures

Sanifitsanifit.com in 𝕏

CSL is a biotechnology company that develops and manufactures plasma-derived and other therapies, including biotherapies for rare and serious diseases, vaccines, and treatments for iron deficiency and kidney disease.

BiotechHealthtechMedical Devices

Joan Perello Bestard(Founder)inCris Calsadain

Co-investorsAndera Partners Columbus Venture Partners Criteria Bio Ventures Invivo Capital Partners

SparingVision’s websitesparingvision.com in 𝕏

SparingVision develops neuroprotective gene therapies for rare genetic diseases affecting the eye and nervous system.

BiotechDeep TechDigital HealthMedical Devices

Co-investorsAdBio partners Jeito Capital

STAT Dxqiagen.com in 𝕏

Qiagen manufactures enzymes and molecular biology products, plus scientific research tools and software for studying biological targets and pathways.

BiotechData & InfrastructureDigital HealthHealthtechMedical Devices

Co-investorsHarmonic Growth Partners Pfizer Venture Investments

Tagworks Pharmaceuticalstagworkspharma.com in 𝕏Jun 2023

Tagworks Pharmaceuticals develops cancer therapies using its Click-to-Release platform, a chemical reaction that activates antibody-drug conjugates (ADCs), masked immunomodulators, and other prodrugs on-target while deactivating radioimmunotherapies off-target.

BiotechHealthtechMedical DevicesNijmegen, NL

Co-investorsBif Lightstone Ventures New Enterprise Associates (NEA)Novartis Venture Fund Clarus Ventures Gilde Healthcare +1 more

TiGenixtakeda.com 𝕏Nov 2017Acquired

Takeda is a global pharmaceutical company that develops medicines and treatments for patients, focused on advancing science, technology, and partnerships to create new standards of care.

BiotechHealthtechTokyo, JP

Claudia D'Augusta(Executive Officer)inEduardo Bravo Fernandez de Araoz(Executive Officer, Director)Marie Paule Richard(Executive Officer)inWilfried Dalemans(Executive Officer)

BoardJune Almenoff(Director)Russell Greig(Director)

Co-investorsKleiner Perkins Rho Ventures Kreos Capital

Xeltisxeltis.com in 𝕏

Xeltis develops implantable vascular devices that transform into living tissue using Restorex supramolecular polymer technology.

BiotechDeep TechHealthtechMedical Devices

Eliane Schutte(Chief Executive Officer)in

Co-investorsKurma Partners VI Partners Amadeus Capital Partners EQT Life Sciences Invest-NL

Other

Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.

GalectoNASDAQ: AURANASDAQ: CVRXNASDAQ: FUSNASDAQ: GLTONASDAQ: KALANASDAQ: LVTXNASDAQ: MLYS

Exits · 8

4 IPOs · 4 acquisitions · showing 7

Aura BiosciencesNASDAQ: AURACVRxNASDAQ: CVRXKALA BIONASDAQ: KALAMineralys TherapeuticsNASDAQ: MLYSMemo Therapeutics AGacq. by ClementiaBioVexacq. by AmgenPrexton Therapeuticsacq. by Lundbeck

Portfolio news

latest coverage across their companies

Ona Therapeutics | Ona Therapeutics Raises $86.6 Million Series B to Advance First-in-Class ADCs into Clinical Development

Ona Therapeutics · ona-therapeutics.com · Jun 4, 2026

SpliceBio Secures $135 Million Series B Financing to Advance Lead Program SB-007 in Stargardt Disease and Expand Pipeline of Genetic Medicines - Splice Bio

Splice Bio · splice.bio · Jun 11, 2025

Frequently asked questions

How many investments has Ysios Capital made?: Ysios Capital has 54 tracked investments, 8 of which have exited, including 1 dated in the last 24 months.
What stage does Ysios Capital invest at?: Ysios Capital invests at the Seed, Series A, Series B, Series C, Growth, Late Stage stages.
What is Ysios Capital's typical check size?: Ysios Capital typically writes checks of $5.4M – $21.6M.
What sectors does Ysios Capital focus on?: Ysios Capital focuses on Biotech, Digital Health, Healthtech, Impact & Social Good, Medical Devices.
Where is Ysios Capital located?: Ysios Capital is headquartered in Barcelona, ES.
Does Ysios Capital lead rounds?: Ysios Capital typically participates in rounds rather than leading them.
Who does Ysios Capital co-invest with?: Ysios Capital most often shares deals with Kurma Partners, Andera Partners, Criteria Bio Ventures, among 71 tracked co-investors.

Media · Podcasts & interviews

featuring the team

Joël Jean-Mairet, General Partner, Ysios Capital

biospaincongress · Joël Jean-Mairet

Bioinvestment - Interview with Karen Wagner (Ysios Capital)

Labiotech.eu · Karen Wagner

Images

Co-investors · 25

Kurma Partners

Kurma Partners is a European healthcare-focused investment firm that co-founds and finances biotech and healthcare companies, working closely with research centers to translate scientific discoveries into high-tech companies.

Both backed · 7

AM Pharma Memo Therapeutics AG Minoryx Therapeutics Synendos Vivet Therapeutics XeltisMedLumics

$162K – $10.8M

Columbus Venture Partners

Columbus Venture Partners is a Spanish life sciences venture firm that invests in therapeutic and industrial biotech products through its life science funds, aiming to advance healthcare while generating returns.

Both backed · 6

Aura Biosciences Minoryx Therapeutics Ona Ona Therapeutics Sanifit Vivet Therapeutics

Forbion

Forbion is a global venture capital firm focused on advancing biotech innovations and other sustainable solutions aimed at improving human and planetary health.

Both backed · 5

AM Pharma Engrail Therapeutics Kynexis Northsea Therapeutics Prexton Therapeutics

Andera Partners

Andera Partners is an asset management firm specializing in private equity that partners with companies and their management to support sustainable growth. It has backed 377 companies over more than 20 years.

Both backed · 5

Mineralys Therapeutics AM Pharma EndoSense SanifitMedLumics

HealthCap

HealthCap is a life science venture capital investor and company creator that backs innovative healthcare ideas, people, and companies aiming to impact healthcare and society.

Both backed · 5

Adcendo BioClin Therapeutics Fusion Pharmaceuticals Vivet TherapeuticsOxthera

Asabys Partners

Asabys Partners is an investment firm based in Barcelona focused on healthcare and life-sciences innovation.

Both backed · 5

Anaconda Biomed Inbiomotion Ona Ona Therapeutics Splice Bio

New Enterprise Associates (NEA)

New Enterprise Associates (NEA) is a venture capital firm that invests in and provides long-term support to founders building new companies.

Both backed · 4

CVRx Clementia Splice Bio Tagworks Pharmaceuticals

$200K – $40M

Novartis Venture Fund

The Novartis Venture Fund invests in innovative life science companies, primarily in biotechnology and biopharmaceuticals, at various stages of development across North America and Europe.

Both backed · 4

Kynexis Splice Bio Tagworks Pharmaceuticals Vivet Therapeutics

$5M – $25M

Roche Venture Fund

Roche Venture Fund is a corporate venture arm that invests in early-stage biotech and diagnostics companies across more than 10 countries, with a portfolio exceeding 30 portfolio companies. The fund is headquartered in Basel, Switzerland.

Both backed · 4

Kidney Minoryx Therapeutics Splice Bio Vivet Therapeutics

$648K – $3.2M

OrbiMed

OrbiMed is a healthcare-focused investment firm providing tailored financing solutions and global resources to build world-class healthcare companies across biopharmaceuticals, medical devices, digital health, diagnostics, and healthcare services.

Both backed · 3

Aura Biosciences Fusion Pharmaceuticals Galecto Biotech

$1M – $75M

EQT Life Sciences

EQT Life Sciences, formerly LSP, is one of Europe's largest and most experienced life sciences investors, backing companies developing therapeutics, medical devices, diagnostics and healthtech globally. It is part of EQT Group.

Both backed · 3

Splice Bio VarmX Xeltis

$11M – $66M

Seventure Partners

Seventure Partners is a European venture capital firm backing innovative companies across life sciences and digital technologies, with additional focus areas in sport & performance and the blue economy.

Both backed · 3

Corwave Cytoki Pharma Galecto Biotech

▶13 more co-investors

Inkef RA Capital Sanofi Ventures Atlas Venture Third Rock Ventures Vida Ventures +ND Capital Action Potential Venture Capital Ltd.Xtripe Angels Versant Ventures Vsquared Ventures Pontifax Venture Capital JMI Equity

Firms observed investing alongside Ysios Capital, from public investor directories. Shared companies are the overlap with Ysios Capital's recorded portfolio.

Similar investors

Novo Holdings

Novo Holdings is the holding and investment company that manages the assets of the Novo Nordisk Foundation, serving as controlling shareholder of Novo Nordisk and Novonesis. It invests in life science companies across all stages and manages a diversified portfolio of equities, bonds, real estate, infrastructure and private equity.

$1.1M – $54M

B4 Capital

$10M – $50M

Lundbeckfonden Ventures

Lundbeckfonden is a Danish foundation that funds health-science research (with a focus on the brain) and invests in and owns healthcare and biotech companies. Its BioCapital arm supports commercialization of biotech science in Denmark and internationally.

MaRS

MaRS Discovery District is Canada's anchor innovation hub, based in Toronto, that supports startups and scale-ups with commercialization guidance, connections to capital, customers and talent, and access to a network of advisors, researchers and partners.

Portfolia

Portfolia operates thematic venture funds designed by and for women investors, backing companies in women's health, active aging, and longevity, alongside a community of over 2,200 women investors across 48 states and 20 countries.

$10K

Featured in lists

Investors & VC Firms in North America Investors & VC Firms in United States Seed Investors & VC Firms Series A Investors & VC Firms Seed Investors & VC Firms in North America Investors & VC Firms in Europe Seed Investors & VC Firms in United States Growth Investors & VC Firms Series A Investors & VC Firms in North America Investors & VC Firms in Global Series B Investors & VC Firms Series A Investors & VC Firms in United States